Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tetsuhiro Tanaka

Showing results (1-10 of 148) with videos related to

Pageof 15
Sort By:
Kidney International|November 21, 2017
PHD in the FOXD1 lineage cells links hypoxia to inappropriate nephrogenesisTetsuhiro Tanaka
Medical Molecular Morphology|July 21, 2016
A mechanistic link between renal ischemia and fibrosisTetsuhiro Tanaka
Clinical and Experimental Nephrology|February 10, 2016
Expanding roles of the hypoxia-response network in chronic kidney diseaseTetsuhiro Tanaka
Nihon Yakurigaku Zasshi. Folia Pharmacologica Japonica|January 7, 2020
[Multiple consequences of HIF activation in CKD]Tetsuhiro Tanaka
Nephron|September 19, 2015
How to Supplement Iron in Patients with Renal AnemiaShinji Tanaka, Tetsuhiro Tanaka
Internal Medicine (Tokyo, Japan)|March 2, 2018
The Anticipated Renoprotective Effects of Sodium-glucose Cotransporter 2 InhibitorsMarie Ito, Tetsuhiro Tanaka
Contributions to Nephrology|January 22, 2011
Pathogenesis of tubular interstitial nephritisTetsuhiro Tanaka, Masaomi Nangaku
Journal of Pharmacological Sciences|January 20, 2009
Drug discovery for overcoming chronic kidney disease (CKD): prolyl-hydroxylase inhibitors to activate hypoxia-inducible factor (HIF) as a novel therapeutic approach in CKDTetsuhiro Tanaka, Masaomi Nangaku
Current Opinion in Nephrology and Hypertension|September 26, 2009
The role of hypoxia, increased oxygen consumption, and hypoxia-inducible factor-1 alpha in progression of chronic kidney diseaseTetsuhiro Tanaka, Masaomi Nangaku
Experimental Cell Research|March 15, 2012
Recent advances and clinical application of erythropoietin and erythropoiesis-stimulating agentsTetsuhiro Tanaka, Masaomi Nangaku
Pageof 15

Showing results (1-10 of 148) with videos related to

Sort By:
Pageof 15
Kidney International|November 21, 2017
PHD in the FOXD1 lineage cells links hypoxia to inappropriate nephrogenesisTetsuhiro Tanaka
Medical Molecular Morphology|July 21, 2016
A mechanistic link between renal ischemia and fibrosisTetsuhiro Tanaka
Clinical and Experimental Nephrology|February 10, 2016
Expanding roles of the hypoxia-response network in chronic kidney diseaseTetsuhiro Tanaka
Nihon Yakurigaku Zasshi. Folia Pharmacologica Japonica|January 7, 2020
[Multiple consequences of HIF activation in CKD]Tetsuhiro Tanaka
Nephron|September 19, 2015
How to Supplement Iron in Patients with Renal AnemiaShinji Tanaka, Tetsuhiro Tanaka
Internal Medicine (Tokyo, Japan)|March 2, 2018
The Anticipated Renoprotective Effects of Sodium-glucose Cotransporter 2 InhibitorsMarie Ito, Tetsuhiro Tanaka
Contributions to Nephrology|January 22, 2011
Pathogenesis of tubular interstitial nephritisTetsuhiro Tanaka, Masaomi Nangaku
Journal of Pharmacological Sciences|January 20, 2009
Drug discovery for overcoming chronic kidney disease (CKD): prolyl-hydroxylase inhibitors to activate hypoxia-inducible factor (HIF) as a novel therapeutic approach in CKDTetsuhiro Tanaka, Masaomi Nangaku
Current Opinion in Nephrology and Hypertension|September 26, 2009
The role of hypoxia, increased oxygen consumption, and hypoxia-inducible factor-1 alpha in progression of chronic kidney diseaseTetsuhiro Tanaka, Masaomi Nangaku
Experimental Cell Research|March 15, 2012
Recent advances and clinical application of erythropoietin and erythropoiesis-stimulating agentsTetsuhiro Tanaka, Masaomi Nangaku
Pageof 15